Drug intelligence / Profile preview

lactobacillus brevis + lactobacillus plantarum

Development stage: Phase 3
Lead developer: Al-Azhar University
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

Lactobacillus brevis + Lactobacillus plantarum is a combination probiotic mixture being investigated as a local delivery drug for the management of Stage III Grade C periodontitis (molar-incisor pattern). Developed by researchers at Al-Azhar University, the treatment is administered as an intra-pocket formula following scaling and root planing (SRP). The probiotic strains work by colonizing the periodontal pocket, competing with pathogenic bacteria for nutrients and adhesion sites, and producing antimicrobial substances. This microbial therapy aims to restore a healthy subgingival microbiome and reduce clinical markers of periodontal disease such as pocket depth and attachment loss.

Other names: Probiotic Formulaintra-pocket probiotic formula

Beyond the preview

Go deeper on lactobacillus brevis + lactobacillus plantarum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus brevis + lactobacillus plantarum.

Explore the full profile